Session Information
Date: Thursday, June 23, 2016
Session Title: Neuropharmacology
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: Our primary aim was comparative study of monotherapy with memantine and combinative therapy with memantine and galantamine hydrobromide for treatment of vascular parkinsonism with early signs of dementia.
Background: Since these pathologies are common in Uzbekistan, it would be interesting for us to investigate their treatment.
Methods: The study included 68 patients diagnosed with vascular parkinsonism and dementia who were treated at Neurology and Therapy departments of the 1st Clinic of Tashkent Medical Academy. The 1st group consisted of 33 patients who took memantine 20 mg / day. The 2nd group patients received combination of memantine 20 mg / day and galantamine hydrobromide 10 mg / day. The average dose of L – dopa in two groups didn’t differ significantly. The dose of memantine in two groups was gradually increased according to common scheme. Duration of study was 2 months. Examination included cognitive function assessment conducted by MMSE and "cognitive" part of the Alzheimer’s Disease Assessment Scale (ADAS-cog).
Results: General improvement was observed in 41% of patients from the 1st group. At the same time, 33% of patients noted subjective improvement in memory, environmental orientation, increase of activity and concentration, all of which lead to enhancement of daily activities. At the 2nd group the figures were 51% and 44% respectively (p <0.001). Patients reported positive effect from the treatment 1 month later. Within 2 months of therapy there was a statistically significant improvement in cognitive performance according to MMSE in patients from the 1st group (MMSE total score increased on 1.0 point, from 19 to 20.0) and from the 2nd group (the figures were risen from 19.0 to 21.0 points).The use of "cognitive" part of the Alzheimer’s Disease Assessment Scale ADAS-cog showed an increase of total score on 2 points in the 1st group and on 3.5 points in the 2nd group.
Conclusions: Combinative therapy of memantine and galantamine hydrobromide has a more positive effect on functions of higher cortical activity than monotherapy with memantine in patients with vascular parkinsonism with early symptoms of dementia.
To cite this abstract in AMA style:
A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov. Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/combinative-therapy-of-memantine-and-galantamine-hydrobromide-as-a-tool-of-choice-for-the-treatment-of-vascular-parkinsonism-with-early-appearance-of-dementia-symptoms/. Accessed November 22, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/combinative-therapy-of-memantine-and-galantamine-hydrobromide-as-a-tool-of-choice-for-the-treatment-of-vascular-parkinsonism-with-early-appearance-of-dementia-symptoms/